Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Stryker (SYK)

Stryker recasts 2023-2025 financials for new Ortho Tech business structure

Neutral Impact 2 of 5 other Written later

Stryker filed an 8-K to recast its consolidated financial statements for the three years ended December 31, 2025, to reflect a reorganization that created the Ortho Tech business. The company states that the recast is not a restatement and does not amend its audited financial statements. The company will continue to report two segments, MedSurg and Neurotechnology, and Orthopaedics.

Key points

  • Ortho Tech combines orthopaedic instruments from the Instruments business with Mako and enabling technologies from Other Orthopaedics.
  • Ortho Tech 2025 net sales were $2,770 million, up 11.8% as reported.
  • The filing covers 2023, 2024 and 2025, with the recast presented in Exhibit 99.1.
  • The filing does not update MD&A; more current information is in the Form 10-Q for the quarter ended March 31, 2026.

The filing

CompanyStryker (SYK)
Form8-K, current report
Filed with the SECJun 26, 2026, 3:45 PM ET
Accession number0000310764-26-000041

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 2:16 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 26, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.